MEDOD2, Undergraduate course / Second Semester Medicine and Dentistry

BMED331: Tumor Biology 

Vitenskapelig artikkel

• Blakstad, Hanne Kristin; Brekke, Jorunn; Rahman, Mohummad Aminur et al. (2023). Survival in a consecutive series of 467 glioblastoma patients: Association with prognostic factors and treatment at recurrence at two independent institutions. (ekstern lenke)
• Hannisdal, Marianne Hjellvik; Goplen, Dorota; Alam, Saruar et al. (2023). Feasibility of deep learning-based tumor segmentation for target delineation and response assessment in grade-4 glioma using multi-parametric MRI. (ekstern lenke)
• Rahman, Mohummad Aminur; Engelsen, Agnete ; Sarowar, Shahin et al. (2022). Bortezomib abrogates temozolomide-induced autophagic flux through an ATG5 dependent pathway. (ekstern lenke)
• Schneider, Matthias; Vollmer, Lea; Potthoff, Anna-Laura et al. (2021). Meclofenamate causes loss of cellular tethering and decoupling of functional networks in glioblastoma. (ekstern lenke)
• Rahman, Mohummad Aminur; Brekke, Jorunn; Arnesen, Victoria Smith et al. (2020). Sequential bortezomib and temozolomide treatment promotes immunological responses in glioblastoma patients with positive clinical outcomes: A phase 1B study. (ekstern lenke)
• Gras Navarro, Andrea; Espedal, Heidi; Vareecal Joseph, Justin et al. (2019). Pretreatment of glioblastoma with bortezomib potentiates natural killer cell cytotoxicity through TRAIL/DR5 mediated apoptosis and prolongs animal survival. (ekstern lenke)
• Leiss, Lina; Mega, Alessandro; Bontell, Thomas Olsson et al. (2019). Platelet‐derived growth factor receptor α/glial fibrillary acidic protein expressing peritumoral astrocytes associate with shorter median overall survival in glioblastoma patients. (ekstern lenke)
• Rahman, Mohummad Aminur; Gras Navarro, Andrea; Brekke, Jorunn et al. (2019). Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival. (ekstern lenke)
• Haspels, Heleen Neeltje; Rahman, Mohummad Aminur; Vareecal Joseph, Justin et al. (2018). Glioblastoma Stem-Like Cells Are More Susceptible Than Differentiated Cells to Natural Killer Cell Lysis Mediated Through Killer Immunoglobulin-Like Receptors-Human Leukocyte Antigen Ligand Mismatch and Activation Receptor-Ligand Interactions. (ekstern lenke)
• Bahador, Marzieh; Gras Navarro, Andrea; Rahman, Mohummad Aminur et al. (2017). Increased infiltration and tolerised antigen-specific CD8+ TEM cells in tumor but not peripheral blood have no impact on survival of HCMV+ glioblastoma patients. (ekstern lenke)
• Leiss, Lina Wik; Mutlu, Ercan; Øyan, Anne Margrete et al. (2017). Tumour-associated glial host cells display a stem-like phenotype with a distinct gene expression profile and promote growth of GBM xenografts. (ekstern lenke)
• Netland, Inger Anne; Førde-Tislevoll, Hilde Elise; Sleire, Linda et al. (2016). Dactolisib (NVP-BEZ235) toxicity in murine brain tumour models. (ekstern lenke)
• Dominguez Valentin, Mev; Gras Navarro, Andrea; Rahman, Mohummad Aminur et al. (2016). Identification of a natural killer cell receptor allele that prolongs survival of cytomegalovirus-positive glioblastoma patients. (ekstern lenke)
• Netland, Inger Anne; Førde-Tislevoll, Hilde Elise; Sleire, Linda et al. (2016). Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM xenografts and prolongs survival in nude rats. (ekstern lenke)
• Kumpf, Robert; Thorstensen, Tage; Rahman, Mohummad Aminur et al. (2014). The ASH1-RELATED3 SET-domain protein controls cell division competence of the meristem and the quiescent center of the arabidopsis primary root. (ekstern lenke)
• Rahman, Mohummad Aminur; Kristiansen, Per Eugen; Veiseth, Silje Veie et al. (2014). The arabidopsis histone methyltransferase SUVR4 binds ubiquitin via a domain with a four-helix bundle structure. (ekstern lenke)
• Kumpf, Robert; Rahman, Mohummad Aminur (2014). ASH1 RELATED3 (ASHR3) encodes a SET domain protein controlling Cell division patterns in the Quiescent Centre and Meristematic Zone of Arabidopsis Roots via Histone 3 Lysine 36 Monomethylation.. (ekstern lenke)
• Hoppmann, Verena; Thorstensen, Tage; Kristiansen, Per Eugen et al. (2011). The CW domain, a new histone recognition module in chromatin proteins. (ekstern lenke)
• Veiseth, Silje Veie; Rahman, Mohummad Aminur; Yap, Kyoko L. et al. (2011). The SUVR4 Histone Lysine Methyltransferase Binds Ubiquitin and Converts H3K9me1 to H3K9me3 on Transposon Chromatin in Arabidopsis. (ekstern lenke)

Vitenskapelig Kapittel/Artikkel/Konferanseartikkel

• Leiss, Lina Wik; Mutlu, Ercan; Rahman, Mohummad Aminur et al. (2022). Tumor–Host Interactions in Malignant Gliomas. (ekstern lenke)

Mastergradsoppgave

• Suntharalingam, Susina; Enger, Martha; Rahman, Mohummad Aminur et al. (2022). Two distinct biomarkers and their role in glioblastoma biological behavior. (ekstern lenke)
• Sarowar, Shahin; Enger, Martha Chekenya; Gras Navarro, Andrea et al. (2016). Treatment with Bortezomib Sensitizes Glioblastoma Cells to Temozolomide. (ekstern lenke)
• Lellahi, Seyed Mohammad; Rahman, Mohummad Aminur; Enger, Per Øyvind (2014). POU3f2 in human gliomas -Expression pattern and functional role. (ekstern lenke)

Poster

• Rahman, Mohummad Aminur; Leiss, Lina Wik; Lellahi, Seyed Mohammad et al. (2015). The transcription factor POU3F2 is expressed in human gliomas and promotes tumorigenesis in vivo. (ekstern lenke)
• Gjerde, Christiane Helgestad; Mutlu, Ercan; Leiss, Lina Wik et al. (2015). FGFR4 is expressed in the tumor and stromal compartments of human gliomas of all grades and histologies.. (ekstern lenke)
• Rahman, Mohummad Aminur; Leiss, Lina Wik; Lellahi, Seyed Mohammad et al. (2014). The transcription factor POU3f2 uniformly express in human gliomas and promotes tumorigenesis and overall growth rate in vivo. (ekstern lenke)

Se en full oversikt over publikasjoner i Cristin

List of major publications in major national or international peer-reviewed journals   

1. Blakstad H, Brekke J, Rahman MA, Arnesen VS, Miletic H, Brandal P, et al. (2023) Survival in a consecutive series of 467 glioblastoma patients: Association with prognostic factors and treatment at recurrence at two independent institutions. PLoS ONE 18(2): e0281166. https://doi.org/10.1371/journal.pone.0281166
2. Hannisdal MH, Goplen D, Alam S, Haasz J, Oltedal L, Rahman MA, Rygh CB, Lie SA, Lundervold A, Chekenya M. Feasibility of deep learning-based tumor segmentation for target delineation and response assessment in grade-4 glioma using multi-parametric MRI. Neurooncol Adv. 2023 Apr 13;5(1):vdad037. doi: 10.1093/noajnl/vdad037.
3. Rahman MA, Engelsen AST, Sarowar S, Bindesbøll C, Birkeland E, Goplen D, Lotsberg ML, Knappskog S, Simonsen A, Chekenya M. Bortezomib abrogates temozolomide-induced autophagic flux through an ATG5 dependent pathway. Front Cell Dev Biol. 2022 Dec 22;10:1022191. doi: 10.3389/fcell.2022.1022191.
4. Schneider M, Vollmer L, Potthoff AL, Ravi VM, Evert BO, Rahman MA, Sarowar S, Kueckelhaus J, Will P, Zurhorst D, Joseph K, Maier JP, Neidert N, d’Errico P, Meyer-Luehmann M, Hofmann UG, Dolf A, Salomoni P, Güresir E, Enger PØ, Chekenya M, Pietsch T, Schuss P, Schnell O, Westhoff, Jürgen Beck M, Vatter H, Waha A, Herrlinger U, Heiland DH. Meclofenamate causes loss of cellular tethering and decoupling of functional networks in glioblastoma. Neuro Oncol. 2021 Apr 17;noab092.
5. Rahman MA, Brekke J, Arnesen V, Waha A, Herfindal L, Rygh CB, Bratland E, Brandal P, Haasz J, Oltedal L, Miletic H, Lundervold A, Lie SA, Goplen D, Chekenya M. Sequential bortezomib and temozolomide treatment promotes immunological responses in glioblastoma patients with positive clinical outcomes. Immunity, Immunology and Disease, 2020 Sep;8(3):342-359. doi: 10.1002/iid3.315. Epub 2020 Jun 24.
6. Leiss L, Mega A, Olsson Bontell T, Nistér M, Smits A, Corvigno S, Rahman MA, Enger PØ, Miletic H, Östman A. Platelet-derived growth factor receptor α/glial fibrillary acidic protein expressing peritumoral astrocytes associate with shorter median overall survival in glioblastoma patients. Glia. 2020 May;68(5):979-988. doi: 10.1002/glia.23756. Epub 2019 Nov 26.
7. Rahman MA, Gras Navarro A, Brekke J, Engelsen A, Bindesbøll C, Sarowar S, Bahador M, Bifulco E, Goplen D, Waha A, Lie SA, Gjertsen BT, Selheim F, Enger PØ, Simonsen A, Chekenya M. Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival. Br J Cancer. 2019 Aug 15. doi: 10.1038/s41416-019-0551-1.
8. Gras Navarro A, Espedal H, Joseph JV, Trachsel-Moncho L, Bahador M, Gjertsen BT, Kristoffersen EK, Simonsen A, Miletic H, Enger PØ, *Rahman MA, *Chekenya M. Pretreatment of Glioblastoma with Bortezomib Potentiates Natural Killer Cell Cytotoxicity through TRAIL/DR5 Mediated Apoptosis and Prolongs Animal Survival. Cancers (Basel) 2019; Jul 17;11(7). 1 *Co-correspondence
9. Haspels H, Rahman MA, Joseph JV, Gras Navarro A and Chekenya M. Glioblastoma stem-like cells are more susceptible than differentiated cells to NK cell lysis mediated through KIR-HLA ligand mismatch and activation receptor-ligand interactions. Frontiers in Immunology 2018; 9: 1345.:
10. Bahador M, Gras Navarro, Rahman MA, Dominguez-Valentin, Sarowar S, Ulvedstad E, Njølstad G, Enger PØ, Lie SA, Kristoffersen EK, Bratland E, Chekenya M. Increased infiltration and tolerised antigen-specific CD8+ TEM cells in tumor but not peripheral blood have no impact on survival of HCMV+ glioblastoma patients. OncoImmunology 2017; 6(8): e1336272.:
11. Leiss L, Mutlu E, Øyan A, Yan T, Tsinkalovsky O, Sleire L, Petersen K, Rahman MA, Johannessen M, Mitra SS, Jacobsen HK, Talasila KM, Miletic H, Jonassen I, Li X, Brons NH, Kalland KH, Wang J, Enger PØ. Tumour-associated glial host cells display a stem-like phenotype with a distinct gene expression profile and promote growth of GBM xenografts. BMC Cancer. 2017 Feb 7;17(1):108. doi: 10.1186/s12885-017-3109-8.
12. Dominguez Valentin M*, Gras Navarro A*, Rahman AM*, Kumar S, Retière C, Ulvestad E, Kristensen V, Lund-Johansen M, Lie BA, Enger PØ, Njølstad G, Kristoffersen E, Lie SA, Chekenya M. Identification of a natural killer cell receptor allele that prolongs survival of cytomegalovirus-positive glioblastoma patients. Cancer Res. 2016 Jul 12. pii: canres.1162. 2016. *equally contributed.
13. Netland IA, Førde HE, Sleire L, Leiss L, Rahman MA, Skeie BS, Gjerde CH, Enger PØ, Goplen D. Dactolisib (NVP-BEZ235) toxicity in murine brain tumour models. BMC Cancer. 2016 Aug 19;16:657. doi: 10.1186/s12885-016-2712-4.
14. Netland IA, Førde HE, Sleire L, Leiss L, Rahman MA, Skeie BS, Miletic H, Enger PØ, Goplen D. Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM xenografts and prolongs survival in nude rats. J Neurooncol. 2016 Aug;129(1):57-66. doi: 10.1007/s11060-016-2158-1. Epub 2016 Jun 9.
15. Rahman MA, Kristiansen PE, Veiseth SV, Andersen JT, Yap KL, Zhou MM, Sandlie I, Thorstensen T, Aalen RB. The arabidopsis histone methyltransferase SUVR4 binds ubiquitin via a domain with a four-helix bundle structure. Biochemistry. 2014 Apr 8;53(13):2091-100.
16. Kumpf R, Thorstensen T, Rahman MA, Heyman J, Nenseth HZ, Lammens T, Herrmann U, Swarup R, Veiseth SV, Emberland G, Bennett MJ, De Veylder L, Aalen RB. The ASH1-RELATED3 SET-domain protein controls cell division competence of the meristem and the quiescent center of the Arabidopsis primary root. Plant Physiol. 2014 Oct;166(2):632-43. doi: 10.1104/pp.114.244798. Epub 2014 Jul 17.
17. Veiseth SV, Rahman MA, Yap KL, Fischer A, Egge-Jacobsen W, Reuter G, Zhou M, Aalen, Reidunn B, Thorstensen T, & Qu L. (2011). The SUVR4 Histone Lysine Methyltransferase Binds Ubiquitin and Converts H3K9me1 to H3K9me3 on Transposon Chromatin in Arabidopsis. PLOS Genetics., 7(3). https://doi.org/10.1371/journal.pgen.1001325
18. Hoppmann V, Thorstensen T, Kristiansen PE, Veiseth SV, Rahman MA, Finne K, Aalen RB, Aasland R. The CW domain, a new histone recognition module in chromatin proteins. EMBO J. 2011 May 18;30(10):1939-52. doi: 10.1038/emboj.2011.108.
19. Rahman MA, Bachar SC, Rahmatullah M. Analgesic and antiinflammatory activity of methanolic extract of Acalypha indica Linn. Pak J Pharm Sci. 2010 Jul;23(3):256-8.
20. Rahmatullah, M., Hasan, M.N., Rahman, M.A., Ali, A.H.M.Z., Nahar, N., Jahan, R., Khatun, A., Ahmed, R., Ahsan, S. and Nasrin, D. (2010) 'School children's intellectual function when exposed to drinking water containing arsenic at Madartola (an arsenic affected area) in Bangladesh', Advances in Environmental Biology, May, 172+,
21. Rahmatullah, M., Das, N.K., Rahman, M.A., Sultana, T., Jahan, R., A Preliminary study on co-cultivation of Mozambique tilapia (Oreochromis mossambicus) with bronze featherback (Notopterus notopterus) in shallow homestead ponds. Indian Journal of Fisheries, Volume 56, Issue 1, January 2009, Pages 43-45

 

Book Chapter

1. Leiss, L., Mutlu, E., Rahman, M. A., Nilsen, M. H., & Enger, P. Øyvind. (n.d.). Tumor–Host Interactions in Malignant Gliomas. In Biomarkers of the Tumor Microenvironment. (2nd ed., pp. 509–518). Springer International Publishing AG. https://doi.org/10.1007/978-3-030-98950-7_30

 

 

Conference proceedings

1. Goplen, D., Rahman, M. A., Brandal, P., Solheim, T. S., Brekke, J., Arnesen, V. S., Oltedal, L., Simonsen, A., Waha, A., Marienhagen, K., Haasz, J., Miletic, H., Lie, S. A., & Chekenya, M. (2023). BORTEM-17: A phase IB/II single arm, multicentre study investigating the efficacy of sequential bortezomib and temozolomide in recurrent GBM with unmethylated MGMT promoter—The results of an interim analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology., 41(16_suppl), 2019–2019. https://doi.org/10.1200/JCO.2023.41.16_suppl.2019
2. Hannisdal, M., Goplen, D., Alam, S., Haasz, J., Oltedal, L., Rahman, M., Rygh, C., Lie, S., Lundervold, A., & Chekenya, M. (2023). PD-0316 Deep learning tumor segmentation for target delineation in glioblastoma using multi-parametric MRI. Radiotherapy and Oncology., 182, S251–S252. https://doi.org/10.1016/S0167-8140(23)08847-3
3. Goplen, D., Rahman, M. A., Brekke, J., Arnesen, V., Simonsen, A., Waha, A., Marienhagen, K., Oltedal, L., Haasz, J., Miletic, H., Solheim, T. S., Brandal, P., Lie, S. A., & Chekenya, M. (2022). Abstract CT114: BORTEM-17 - phase IB/II single arm, non-randomized controlled multicenter study investigating whether sequential bortezomib and temozolomide is safe and effective in recurrent GBM with unmethylated MGMT promoter. Cancer Research : a Monthly Journal of Articles and Abstracts Reporting Cancer Research : the Official Organ of the American Association for Cancer Research, 82(12_Supplement), CT114–CT114. https://doi.org/10.1158/1538-7445.AM2022-CT114
4. Arnesen, V. S., Suntharalingam, S., Matuszek, Żaneta, Sarowar, S., Knappskog, S., Lie, S. A., Liu, D. R., Rahman, M. A., & Chekenya, M. (2022). Abstract 3996: A novel 13-basepair deletion in CSPG4/NG2 abrogates protein expression, glioblastoma proliferation and invasion in vitro and in vivo in mice. Cancer Research : a Monthly Journal of Articles and Abstracts Reporting Cancer Research : the Official Organ of the American Association for Cancer Research, 82(12_Supplement), 3996–3996. https://doi.org/10.1158/1538-7445.AM2022-3996
5. Goplen, D., Rahman, M. A., Brekke, J., Arnesen, V. S., Simonsen, A., Waha, A., Marienhagen, K., Oltedal, L., Haasz, J., Miletic, H., Solheim, T. S., Brandal, P., Lie, S. A., & Chekenya, M. (2022). Bortezomib sensitization of recurrent glioblastoma with unmethylated MGMT promoter to temozolomide, a phase II study (NCT03643549). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology., 40(16_suppl), TPS2081–TPS2081. https://doi.org/10.1200/JCO.2022.40.16_suppl.TPS2081
6. Blakstad, H., Brekke, J., Rahman, M. A., Arnesen, V. S., Brandal, P., Lie, S. A., Chekenya, M., & Goplen, D. (2021). P14.65 Survival in a consecutive series of 467 glioblastoma patients: impact of prognostic factors and recurrent treatment at two independent institutions. Neuro-Oncology., 23(Supplement_2), ii50–ii50. https://doi.org/10.1093/neuonc/noab180.173
7. Goplen, D., Rahman, M. A., Arnesen, V. S., Brekke, J., Simonsen, A., Andreas, W., Marienhagen, K., Oltedal, L., Haasz, J., Miletic, H., Solheim, T. S., Brandal, P., Lie, S. A., & Chekenya, M. (2021). P14.09 BORTEM-17: A Phase IB/II Single-Arm, Control Non-Randomized, Multicentre, Open Label Clinical Trial for Recurrent Glioblastoma with unmethylated MGMT promoter (NCT03643549). Neuro-Oncology., 23(Supplement_2), ii39–ii39. https://doi.org/10.1093/neuonc/noab180.135
8. Rahman, M. A., Navarro, A. G., Brekke, J., Bindesbøll, C., Engelsen, A., Sarowar, S., Bahador, M., Gjertsen, B. T., Goplen, D., Enger, P. Ø, Selheim, F., Simonsen, A., & Chekenya, M. (2018). Abstract 2928: Bortezomib sensitizes glioblastoma with unmethylated MGMT promoter to temozolomide-chemotherapy through MGMT depletion and abrogated autophagy flux. Cancer Research : a Monthly Journal of Articles and Abstracts Reporting Cancer Research : the Official Organ of the American Association for Cancer Research, 78(13_Supplement), 2928–2928. https://doi.org/10.1158/1538-7445.AM2018-2928
9. Navarro, A. G., Rahman, A., Bahador, M., & Enger, M. C. (2017). Abstract LB-195: Bortezomib sensitizes glioblastoma for NK cell immunotherapy. Cancer Research : a Monthly Journal of Articles and Abstracts Reporting Cancer Research : the Official Organ of the American Association for Cancer Research, 77(13_Supplement), LB–195–LB–195. https://doi.org/10.1158/1538-7445.AM2017-LB-195
10. Rahman, M. A., Liess, L., Lellahi, M. S., Gjerde, C. H., Saed, H. S., Mutlu, E., Zhu, H., Wang, J., & Enger, P. Øyvind. (2015). Abstract 2101: The transcription factor POU3F2 is expressed in human gliomas and promotes tumorigenesis in vivo. Cancer Research : a Monthly Journal of Articles and Abstracts Reporting Cancer Research : the Official Organ of the American Association for Cancer Research, 75(15_Supplement), 2101–2101. https://doi.org/10.1158/1538-7445.AM2015-2101
11. Gjerde, C. H., Mutlu, E., Leiss, L., Kristensen, B. W., Rahman, M. A., & Enger, P. Øyvind. (2015). Abstract 1560: FGFR4 is expressed in the tumor and stromal compartments of human gliomas of all grades and histologies. Cancer Research : a Monthly Journal of Articles and Abstracts Reporting Cancer Research : the Official Organ of the American Association for Cancer Research, 75(15_Supplement), 1560–1560. https://doi.org/10.1158/1538-7445.AM2015-1560
12. Rahman, M. A., Leiss, L., Lellahi, M. S., Gjerde, C. H., Saed, H. S., Mutlu, E., & Enger, P. O. (2014). CS-28 * THE TRANSCRIPTION FACTOR POU3f2 UNIFORMLY EXPRESS IN HUMAN GLIOMAS AND PROMOTES TUMORIGENESIS AND OVERALL GROWTH RATE IN VIVO. Neuro-Oncology., 16(Suppl 5), v57–v57. https://doi.org/10.1093/neuonc/nou242.28
13. Rahman, M. A., Leiss, L., Saed, H. S., Gjerde, C. H., Lellahi, M. S., Mutlu, E., & Enger, P. Øyvind. (2014). Abstract LB-75: Oct7 is expressed in human gliomas and correlates with malignancy grade. Cancer Research : a Monthly Journal of Articles and Abstracts Reporting Cancer Research : the Official Organ of the American Association for Cancer Research, 74(19_Supplement), LB–75–LB–75. https://doi.org/10.1158/1538-7445.AM2014-LB-75
14. Rahman MA, Sandvik SV, Thorstensen T, Davies W, Aalene RB. Arabdiopsis SET-domain Proteins with Different Histone Methyltransferase Activity. InACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES 2009 Jan 1 (Vol. 65, pp. S157-S158). 2 ABBEY SQ, CHESTER, CH1 2HU, ENGLAND: INT UNION CRYSTALLOGRAPHY.

 

Projects:

• BORTEM-17 Phase IB/II trial: investigating the safety and survival benefits for patients with recurrent glioblastoma with unmethylated MGMT promoter treated with Bortezomib and Temozolomide in a specific schedule.
• Identifying novel drugs to sensitize glioblastoma (GBM) cells to Temozolomide chemotherapy: Approximately 50% of the glioblastoma (GBM) patients with unmethylated MGMT promoter gain marginal benefit from Temozolomide chemotherapy.  My project is focused on investigating the novel drugs combinations that may potentiate the efficacy of Temozolomide chemotherapy and/or radiotherapy against GBM.
• Bioinformatic analysis of sequencing data: This project aims to identify immune and cancer related genes that may inform disease associations or impact prognosis, respectively. I use large population databases including sequencing data deposited in The Cancer Genome Atlas project (TCGA), 1000 genomes as well as sequencing data from our local biobanks (patients and healthy population).
• Characterization of epigenetic changes in immune cell subsets as a result of prior human cytomegalovirus infection in brain tumor patients.
• Characterization of adaptive NK cell phenotype in blood and tissue of cytomegalovirus seropositive glioblastoma patients